Synsight leverages machine learning and deep learning to discover new patterns and expand therapeutic options, optimizing the drug discovery process.
Sysnsight specializes in molecular modeling, bioinformatic and structural biology fields. It offers high quality services to improve and accelerate research for pharmaceutical and cosmetic industries. Its services is integratable into more important research programs as a CRO such as protein design, diagnostic kit conception or drug discovery.
Évry (France) 2013 1 - 10 Acquired, July 2024 8 months ago
Sinopia Biosciences effectively leverages machine learning and multi-omics data to discover new patterns and expand therapeutic options, optimizing the drug discovery process.
Sinopia Biosciences is transforming drug discovery and illness research. For the past thirty years, target-based drug discovery has been the predominant method. However, phenotypic screening has shown greater productivity in the discovery of first-in-class medications due to the fact that the pathogenesis of many diseases is often complex and the etiology of many diseases is unclear.
San Diego (United States) 2014 1 - 10 $16.61M Grant, $2.20M, September 12, 2024 8 months ago
Applied Discoveries effectively leverages machine learning and pattern discovery to develop new therapeutics, optimizing the drug discovery process.
Applied Discoveries utilizes a proprietary platform for natural compound discovery and small-molecule therapeutic development. The company develops small-molecule therapeutics for biotechnology research and regulatory approval. The company is based in Eugene, Oregon, and was founded in 2022.
Eugene (United States) 2022 1 - 10 NA 8 months ago
SoftMining effectively leverages machine learning and pattern discovery to expand therapeutics, optimizing the drug discovery process with innovative AI technologies.
SoftMining developed theoretical models for the general applicability of query techniques and semantic analysis. They discovered that two molecules with antitumor activity have entered clinical trials, and a new technique for chemical synthesis on a solid support has been developed.
Fisciano (Italy) 2019 1 - 10 NA 8 months ago
Metanovas effectively leverages machine learning and AI to enhance drug discovery, pattern discovery, and expand therapeutic options.
Metanovas develops nutraceutical and cosmeceutical products with revolutionary AI technology. The company's product pipeline includes pharmaceuticals, nutritional supplements, functional foods, and cosmetics, providing patients and consumers with better goods. Metanovas alters how science and AI are used to generate health products.
Mountain View (United States) 2021 11 - 50 $10.00M Series A, December 3, 2024 8 months ago
Metanovas effectively leverages machine learning for drug discovery and repurposing, demonstrating a strong commitment to expanding therapeutic options.
Metanovas develops nutraceutical and cosmeceutical products with revolutionary AI technology. The company's product pipeline includes pharmaceuticals, nutritional supplements, functional foods, and cosmetics, providing patients and consumers with better goods. Metanovas alters how science and AI are used to generate health products.
Mountain View (United States) 2021 11 - 50 $10.00M Series A, December 3, 2024 8 months ago
VeriSIM Life effectively leverages machine learning to enhance drug development, discover patterns in drug interactions, and expand therapeutic options, including drug repurposing.
VeriSIM Life is a computational bioplatform that predicts the clinical outcomes of new drugs before clinical trials. VeriSIM offers a range of translational-based solutions, customized for the pre-clinical and clinical programs. These offerings are all centered around their proven and validated BIOiSIMTM platform for small molecules, large molecules, and viruses.
San Francisco (United States) 2017 11 - 50 $21.66M Series A, $15.00M, January 13, 2022 8 months ago
Pending.AI effectively utilizes machine learning to enhance drug discovery, pattern discovery, and the development of new therapeutics.
Founded by Professor Mark Waller, Pending AI has developed a comprehensive discovery platform enabled by artificial intelligence and quantum mechanics, ushering in a new paradigm of medicinal innovation where higher-quality small molecule drugs can be developed in a fraction of the time and cost. With operational presences across both Cambridge, Massachusetts, United States and Eveleigh, New South Wales, Australia, Pending AI is actively seeking research-and-development partnerships with pharmaceutical companies, as well as to ascertain interest from investors in the company's upcoming investment round.
Cambridge (United States) 2018 1 - 10 Venture - Series Unknown, January 1, 2021 8 months ago
REPO4EU effectively leverages machine learning for drug repurposing, discovering new patterns in disease mechanisms, and expanding therapeutic options.
This platform will operate as a data hub for key information, training resources, matchmaking and collaboration in drug repurposing. We offer a world-class mix of applied bioinformatics, innovative diagnostics, curative drug therapies, expertise in repurposed drug patenting, freedom to operate, business development, health technology assessment and multiple options for value creation through licensing and spin-offs.
Maastricht (Netherlands) 2022 11 - 50 NA 8 months ago
Cancerappy effectively utilizes machine learning and AI to enhance cancer research, discover new therapeutic targets, and optimize drug discovery processes.
Cancerappy designs and develops a platform that uses big data and artificial intelligence to help research against cancer. Luis Martín Ezama founded it in 2019, with its headquarters in Bilbao in Spain.
Bilbao (Spain) 2019 1 - 10 NA 8 months ago
Fasttrac leverages machine learning and advanced computational methods to discover novel molecules, optimizing the drug discovery process and expanding therapeutic options.
Fasttrac Enables the discovery of novel molecules for drug development and materials applications, fasttrac repository - contributing services, physics, chemistry, biology, and mathematics-based software services.
Irvine (United States) 2019 11 - 50 NA 8 months ago
Insitro effectively utilizes machine learning to discover patterns and expand therapeutics, optimizing the drug discovery process.
Insitro is an operator of a data-driven drug discovery and development company that utilizes machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company uses state-of-the-art technologies from bioengineering enabling it to generate high-throughput, functional genomic data sets and aligning them with patient data via novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics. In 2018, Daphne Koller established Insitro in South San Francisco, California..
South San Francisco (United States) 2018 201 - 500 $643.00M Series C, $400.00M, March 15, 2021 8 months ago
Medvolt effectively leverages machine learning to discover patterns and expand therapeutics, including drug repurposing capabilities.
Developer of biomedical research platform designed to accelerate life sciences research. The company focuses on accelerating drug discovery and development by democratizing access to AI-powered technology and clean data by leveraging a highly modular and data-driven, thereby reducing costs and increasing the probability of success.
Pune (India) 2021 1 - 10 NA 8 months ago
Illumina specializes in advanced technologies for analyzing genetic material, focusing on DNA, RNA, and protein analysis to support disease research and drug development. Their solutions aim to facilitate personalized medicine through innovative and scalable approaches.
Illumina is an innovative technology and revolutionary assay aiming to analyze genetic variation and function. These studies help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission-critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a company that places a high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, it strives to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Biomarker Identification
+1
San Diego (United States) 1998 5001 - 10000 $1.37B Post-IPO Debt, $500.00M, September 6, 2024 8 months ago
Quanterix Corporation develops a highly sensitive platform for analyzing individual proteins and small molecules, enhancing clinical diagnostics and drug development. Their technology enables early disease detection and precise treatment methods across various therapeutic areas.
Quanterix Corporation is developing a novel platform for single-molecule analysis that will bring an unprecedented level of sensitivity, precision, and assay robustness to clinical diagnostics, drug development, and life science research. Their unique approach permits rapid quantification and analysis of individual proteins and small molecules within complex biological samples, enabling us to address a variety of unmet medical needs. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’s technology is designed to enable much earlier disease detection, better prognosis, and precise treatment methods to improve the quality of life and longevity of the population for generations to come.
Billerica (United States) 2007 201 - 500 $597.30M Grant, March 29, 2022 8 months ago
GeneOmics Solutions effectively leverages machine learning for diagnosis, discovers new patterns in data, and expands therapeutic options through its research initiatives.
Developer of personalized medicine sequencing data analysis solutions. GeneOmics Solutions integrates multi-omics data to enable research for the discovery of biomarkers and therapies for diseases such as cancers, rare diseases, autoimmune, and infectious diseases. The company offers custom pipeline development, automation and standardization, data analytical and statistical tools, data connectivity, and purpose-built dashboards to enable the discovery of biomarkers and therapeutic targets. GeneOmics Solutions specializes in AI and machine learning solutions for diagnosis and collaborates with research partners.
2018 1 - 10 NA 8 months ago
Genome International Corporation leverages machine learning and advanced algorithms to discover genetic patterns and enhance therapeutic options in genomic medicine.
Genome International Corporation (GIC) is a research-driven firm providing innovative bioinformatics products and custom research solutions for corporate, government, and academic laboratories in biomedical sciences. Their scientists and engineers are passionate about delivering high quality yet cost effective products and services by innovating advances in bioinformatics and information technologies to optimize the management, analysis and mining of high-throughput molecular biology data.
Madison (United States) 1992 51 - 200 NA 8 months ago
Koonkie leverages machine learning for genomic data analysis, discovers biological patterns, and aims to expand therapeutic options through optimized product development.
Koonkie has helped find therapeutic targets, kick start environmental recovery and reclamation, find new species and discover life's strategy for survival on Earth. Our team specializes in integrating a wide range of physical, chemical and biological measurements with genomic sequence information to optimize product development and improve process controls across industrial and health care sectors.
Menlo Park (United States) 2016 11 - 50 Pre-Seed, March 1, 2020 8 months ago
InhibOx leverages advanced machine learning technologies and pattern discovery methods to expand therapeutic options, particularly in the development of novel antibiotics.
InhibOx is a pioneer in the development and application of new technologies to drive drug discovery. Their multidisciplinary research team has brought together breakthroughs in computational chemistry, cheminformatics, mathematics, cloud computing and software-as-a-service (SaaS) delivery methods to create DrugFinder: the next generation drug discovery platform.
Oxford (United Kingdom) 2001 1 - 10 $12.53M Grant, $1.26M, February 20, 2025 8 months ago
Pumeirui leverages machine learning and innovative algorithms to enhance drug discovery, focusing on expanding therapeutics and optimizing the development process.
Pumeirui is a biological research and development algorithm platform service provider. The company focuses on the development of algorithm tools to accelerate the discovery of innovative drugs and the development of anti-tumor target pipelines. Based on cutting-edge technologies such as artificial intelligence, molecular simulation, and cloud computing, it develops innovative algorithms to improve new drugs. The efficiency of research and development.
Changzhou (China) 2020 11 - 50 Pre-Seed, November 29, 2021 8 months ago
Quant Biomarkers leverages machine learning for pattern discovery and therapeutic target identification, focusing on personalized biomarker development.
Specialises in the quantitative assessment of Biomarkers of Human Longevity, the development of personalised biomarker panels of aging, and oncology, fields which target established Hallmarks of Aging. It also supports investment de-risking across various sectors, including R&D and clinical and health insurance. Quant Biomarkers is an AI and tech-powered platform that will further contribute to the creation of structured financial products and analytics linked to biological age. Its main goal is the synthesis and validation of a tangible, effective, and personalized assessment approach that supports interventions and Longevity Medicine therapeutic modalities. The company will also serve as an incubator, IP accelerator, and investment vehicle for the Longevity Biomarkers sector, acquiring the most prospective start-ups, teams, and R&D facilities in the industry for the development of Longevity Preventive Medicine and Precision Health products as well as financial and analytical services.
Basel (Switzerland) 2021 1 - 10 NA 8 months ago
Divergene leverages machine learning to enhance genomic data analysis and supports the expansion of therapeutics in gene therapy.
Developer of AI-driven analytics and informatics for the cell and gene therapy and bioprocessing industries. Divergene's services integrate multimodal data, break down data silos, and create advanced machine learning models to offer actionable insights. Their platform provides a secure and accessible environment for the standardization, computation, and analysis of multimodal data, helping organizations to retain ownership of their samples and data. Divergene collaborates with CROs, CDMOs, and cell and gene therapy companies to enhance their next-generation sequencing capabilities.
United States 1 - 10 NA 8 months ago
GTN effectively utilizes machine learning and pattern discovery to innovate drug discovery, expanding therapeutics and optimizing the process.
Bringing a single new drug to the market costs $2.9bn, often delivering an intervention that barely differs from those already in the market. Projections into the future are not promising, with an expected 50% drop in R&D output every nine years. At GTN they are searching the astronomically large space of drug-like molecules with their unique patented technology, Generative Tensorial Networks. Their software combines and builds upon techniques from machine learning and quantum physics to simulate, filter and search for molecules, halving development costs and discovering molecules entirely hidden from view.
London (United Kingdom) 2017 11 - 50 $2.84M Seed, November 1, 2018 8 months ago
Valence Labs effectively leverages machine learning to discover patterns and expand therapeutics, while optimizing the drug discovery process.
Developer of artificial intelligence-based drug discovery platform designed to unlock small and noisy datasets. The company's platform uses bioinformatics and artificial intelligence to optimize the development of drugs through predictive analytics and work with the small and noisy datasets characteristic of low-throughput compound screens and late-stage lead optimization, enabling pharmaceutical companies to reduce the time, design, and optimize novel ligands against a broad range of precision medicine targets.
Montréal (Canada) 2018 11 - 50 NA 8 months ago
SOM Biotech leverages machine learning for drug discovery, identifies new patterns for therapeutic development, and actively engages in drug repurposing for orphan diseases.
SOM Biotech is a drug innovation company based on a pioneering AI-based drug discovery technology – SOM AI PRO -, that has built a robust pipeline focused mainly on Orphan CNS products with very high unmet need and blockbuster potential. SOM AI PRO has been validated with 2 successful Phase 2 trials (TTR Amyloidosis, Chorea in Huntington disease), and four programs are at the preclinical stage. SOM Biotech applies the proprietary AI-based drug discovery technology for building its pipeline and strategic collaborations with the companies. The AI technology can be applied in any therapeutic area and allows advancing drug candidates into Phase 2a in less than one year (through 505b2 pathway). It also allows improving the effectiveness of drug discovery and drug life cycle management by the identification of novel targets and indications for the molecules.
Barcelona (Spain) 2009 11 - 50 $9.97M Venture - Series Unknown, January 1, 2021 8 months ago
